

**PARTICIPANTS FROM GREECE**  
**REGISTRATION AND PAYMENT INFORMATION**  
**IV<sup>th</sup> Conference on Stem Cell Gene Therapy**

Registration									
Name			Degree/Title						
	First	Last							
Institution			Lab	(Students/Fellows: Enter name of your lab director.)					
Address									
Street			City			State			
		Postal Code		Country					
Telephone			FAX			E-mail			
Registration Fee									
Students or fellows			€ 200						
Other academic			€ 280						
Industry			€ 360						
			<b>TOTAL</b>						
Accommodation Fees									
<b>This includes 4 nights hotel, all meals*, coffee breaks and group transportation to/from Thessaloniki Airport and Hotel Athos</b>									
Single Occupancy			€ 575						
Double Occupancy *			€ 455 (EACH)						
			<b>TOTAL</b>						
Additional Guest Fees									
Guest, Accommodation and breakfast only (in shared double room)			€ 240						
Guest, Accommodation and Full Meals, including Welcome Reception (in shared double room)			€ 455						
Guest, Welcome Reception Only			€ 30						
			<b>TOTAL</b>						
			<b>GRAND TOTAL</b>						
*If you wish to share a room, please include his/her name									
**If you have special dietary requirements please specify									
Any additional information (e.g. disabled accommodation)									
Payment Information									
<b>Name of Participant:</b>									
<b>Total charge (from Registration form)</b>									
			€						
Payment by Credit Card									
• We accept Visa, MasterCard, and American Express credit cards for registration and accommodation fees.									
• Please use the credit card authorization form below:									
Name as it appears on card (please print)									
VISA		MASTERCARD		AMERICAN EXPRESS					
Account Number:			Exp. Date MM/YY:						
<b>AUTHORIZED SIGNATURE</b>									
<b>Please FAX this form to: Nina Thomopoulou - FAX: 30 210 7254363</b>									

**PRELIMINARY PROGRAM**

**10:30 AM SESSION VIII – *Thalassemia and Sickle Cell Disease – continues***  
**David Bodine**, Bethesda, USA  
*Novel vectors for globin gene therapy using regulatory elements from non-globin genes*  
**Punam Malik**, Cincinnati, USA  
*Gene Therapy for Hemoglobinopathies*  
**Derek Persons**, Memphis, USA  
*Gamma-Globin Lentiviral Vector-Mediated Stem Cell Gene Therapy of Beta-Thalassemia and Sickle Cell Disease*

**12:00 PM SESSION IX – *Fanconi Anemia***  
**Juan Bueren**, Madrid, Spain  
*Towards the Gene Therapy of Fanconi Anemia Patients with Lentiviral Vectors*  
**David Williams**, Cincinnati, USA  
*Too little, too late: the initial experience in FA gene therapy*

**12:30 PM SESSION X – *Panel discussion: What is the optimal BM conditioning for stem cell gene therapy?***  
**Guido Lucarelli**, Roma, Italy  
**Maria Grazia Roncarolo**, Milano, Italy  
**Athanasios Fassas**, Thessaloniki, Greece  
**General Discussion**

**2:00 PM** Break for Lunch

**3:00 PM Poster Session C**

**6:30 PM** Dinner

**7:30 PM SESSION XI – *Gene Therapy of Cancer***  
**Claudio Bordignon**, Milano, Italy  
*T cell-based immunogene therapy of cancer*  
**David Williams**, Cincinnati, USA  
*Too much of a good thing? MGMT in chemoresistance and brain tumor therapy*  
**Chiara Bonini**, Milano, Italy  
*Suicide immune-gene therapy in hematopoietic stem cell transplantation*  
**Masafumi Onodera**, Tsukuba Science City, Japan  
*Opposite effects of an integration site on expression of the transgene - Gene silencing or Leukemogenesis*  
**C. Anthony Blau**, Seattle, USA  
*Erythropoietin Blockade for the Treatment of Cancer*

**ORGANIZING COMMITTEE**

*Co-Chair:*  
**G. Stamatoyannopoulos**

*Co-Chair:*  
**Luigi Naldini**

**Arthur W. Nienhuis**  
**David M. Bodine**  
**Claudio Bordignon**

**Evangelia Yannaki**  
**Christopher Baum**  
**Adrian Thrasher**

**LOCAL ORGANIZING COMMITTEE**

*President:* **Achilles Anagnostopoulos**

*Members:*

**Nikolaos Anagnou**  
**Aglaia Athanasiadou**  
**George Vassilopoulos**  
**Spyros Georgatos**  
**Ioannis Dervenoulas**  
**Nikolaos Zoumpos**  
**Dimitrios Karakasis**

**George Kollias**  
**George Bourikas**  
**Eleni Papadaki**  
**George Paterakis**  
**Alexandros Spyridonidis**  
**Konstantinos Tsatalas**  
**Athanasios Fassas**

**INQUIRIES**  
[gstam@u.washington.edu](mailto:gstam@u.washington.edu) or [alicial@u.washington.edu](mailto:alicial@u.washington.edu)

**Informations - Registrations**  
Congress Secretariat **EPSILON**  
4, PAPADIAMANTOPOULOU Str., 115 28, Athens, Greece  
Tel. 2107254360-2 fax. 2107254363  
E-mail: [info@epsiloncongress.gr](mailto:info@epsiloncongress.gr)  
<http://www.epsiloncongress.gr>

**Registrations Fees:**  
Students or Fellows ..... 200 EUROS  
Other Academic ..... 280 EUROS  
Industry..... 360 EUROS

**UNIVERSITY OF WASHINGTON, SEATTLE**  
**HELLENIC SOCIETY OF HAEMATOLOGY**



**IV<sup>th</sup> CONFERENCE**  
**ON STEM CELL GENE**  
**THERAPY**

**PRELIMINARY PROGRAM**

**Chalkidiki, Thessaloniki, Greece**  
**September 13 - 17, 2007**  
**HOTEL ATHOS PALACE**

## INVITATION

Dear Friends,

It is my honor to invite you to participate in a highly significant International Scientific Meeting, the IVth Conference on Stem Cell Gene Therapy which will be held in Halkidiki (Chalkidiki) 13-17 September 2007. This year the Conference is transferred outside the USA under the decision of the organizer of the meeting, George Stamatoyannopoulos, whose wish is for this change to highlight the significant contributions of the European researchers in the recent breakthrough developments in the gene therapy field.

Gene therapy is rapidly being developed in order to target therapeutically a broad spectrum of human diseases. Currently, gene therapy approaches are being tested in many clinical trials (for Congenital Immunodeficiencies, Cancer, GVHD, Thalassaemia, AIDS, and Parkinson's disease). The Conference aims to focus on diseases that require correction at the stem cell level to ensure long-term transgene function and expression. This conference will bring together all the great contributors in the field of stem cell gene therapy who will present the recent developments and try to address the emerging challenges. The Conference will be attended by a worldwide scientific audience. It is a unique opportunity for the Greek and Balkan colleagues to benefit in their research, not only for those who are directly or indirectly involved in this particular field but also for those who wish to gain a thorough introduction in upcoming developments.

The Hellenic Society of Haematology is proud to participate and contribute to the organization of the Conference. It owes this honor and gratitude to its distinguished member, professor and academic, George Stamatoyannopoulos.

Medical doctors, PhDs, biologists, technicians, students and other medical professionals are encouraged to participate. It will be our pleasure to welcome you to the charming Chalkidiki and share with you unique scientific experiences in an unforgettable scenery.

**Achilles Anagnostopoulos**  
**President of the Board of Directors of HSH**  
**And the Local Organizing Committee**

## PRELIMINARY PROGRAM

### Thursday September 13, 2007

- 6:00 PM** Welcome Cocktail
- 7:00 PM** Welcome Reception

### Friday September 14, 2007

- 7:00 AM** Breakfast
- 8:00 AM** Welcome
- 8:10 AM** **SESSION I – Gene transfer systems for stem cell gene therapy: State-of-the-art and novel developments**  
**Luigi Naldini**, Milano, Italy  
*Improving safety and efficacy of HSC gene transfer by lentiviral vectors*  
**David Russell**, Seattle, USA  
*Safety and Efficacy of Foamy Virus Vectors*  
**George Vassilopoulos**, Athens, Greece  
*Stem Cell Gene Transfer with Foamy Virus Vectors*  
**Christof von Kalle**, Heidelberg, Germany  
*The clonal fate of gene corrected myelo- and lymphopoiesis*

- 10:00 AM** Coffee Break

- 10:30 AM** **SESSION II - Gene transfer systems for stem cell gene therapy: Insertional mutagenesis and genotoxicity**  
**Christopher Baum**, Cincinnati, USA  
*Retroviral transgenesis and oncogenesis*  
**Cynthia Dunbar**, Bethesda, USA  
*Genotoxicity in the Rhesus Macaque Model*  
**Arthur W. Nienhuis**, Memphis, USA  
*Retroviral Insertion into the LMO2 gene by rAAV homologous gene targeting and Cre recombinase mediated cassette exchange*  
**Fulvio Mavilio**, Milano, Italy  
*Interactions between retroviral vectors and the genome of CD34+ hematopoietic cells*  
**David Emery**, Seattle, USA  
*Reducing Retroviral Vector Genotoxicity with Chromatin Insulators*

- 1:20 PM** Break for Lunch

## PRELIMINARY PROGRAM

- 2:30 PM** **Poster Session A**
- 6:30 PM** Dinner
- 7:30 PM** **SESSION III – Stem cell biology and leukemia stem cells**  
**Stanton Gerson**, Cleveland, USA  
*DNA repair and the aging of stem cells*  
**Stefan Karlsson**, Lund, Sweden  
*The role of Smad signaling in hematopoiesis*  
**Thalia Papayannopoulou**, Seattle, USA  
*Homing of ex vivo incubated cells: can it be improved?*  
**Dominique Bonnet**, London, UK  
*Leukaemic stem cells: new targets for therapies*

### Saturday September 15, 2007

- 7:00 AM** Breakfast
- 8:00 AM** **SESSION IV – Hematopoietic stem cell expansion and in vivo selection**  
**Hans-Peter Kiem**, Seattle, USA  
*In vivo selection of gene-modified stem cells in a large animal model*  
**Keith Humphries**, Vancouver, Canada  
*Self-renewal programs as a target for gene therapy purposes*
- 9:00 AM** **SESSION V – Gene targeting and repair strategies**  
**David Russell**, Seattle, USA  
*Gene targeting with AAV*  
**Philip Gregory**, Richmond, USA  
*Precision Editing of the Human Genome with Engineered Zinc Finger Proteins*  
**Andre Lieber**, Seattle, USA  
*Adenovirus vectors for targeted integration into human hematopoietic stem cells*

- 10:30 AM** Coffee Break

- 11:00 AM** **SESSION VI – Immune deficiency syndromes**  
**Alessandro Aiuti**, Milano, Italy  
*Hematopoietic stem cell gene therapy for ADA-SCID*  
**Adrian Thrasher**, London, UK  
*Successful reconstitution of immunity following gene therapy for SCID*

## PRELIMINARY PROGRAM

- Marina Cavazzana-Calvo**, Paris, France  
*Gene therapy targeting hematopoietic stem cells: from the bench to the bedside*  
**Brian Sorrentino**, Memphis, USA  
*Factors Involved in Transformation in XSCID Gene Therapy*
- 1:30 PM** Break for Lunch
- 3:00 PM** **Poster Session B**
- 6:30 PM** Dinner
- 7:30 PM** **Session VI – Immune deficiency syndromes –continues**  
**Tadashi Ariga**, Sapporo, Japan  
*Hematopoietic stem cell gene therapy for ADA deficiency without cytoreductive conditioning*  
**Fabio Candotti**, Milan, ITALY  
*Gene Therapy for ADA-deficiency in the USA*  
**Maria Grazia Roncarolo**, Milan, ITALY  
*Gene therapy for Wiskott-Aldrich syndrome*
- 9:00 PM** **SESSION VII – Chronic Granulomatous Disease**  
**Manuel Grez**, Frankfurt, Germany  
*Phase I Gene Therapy Study for X-CGD: Results, Lessons and Perspectives*  
**Harry Malech**, Bethesda, USA  
*Update on Gene Therapy for Chronic Granulomatous Disease*

### Sunday September 16, 2007

- 7:00 AM** Breakfast
- 8:00 AM** **SESSION VIII – Thalassemia and Sickle Cell Disease**  
**Philippe Leboulch**, Boston, USA  
*Globin gene transfer and in vivo cell expansion*  
**Evangelia Yannaki**, Thessaloniki, Greece  
*A mobilization study in  $\beta$ -major thalassemia*  
**Michel Sadelain**, New York, USA  
*Transcriptional and post-transcriptional gene regulation in stem cell-based gene therapy*  
**Giuliana Ferrari**, Milano, Italy  
*Preclinical assessment of gene therapy for beta thalassemia*
- 10:00 AM** Coffee Break

To the  
Congress Secretariat of the  
IVth Conference on Stem Cell Gene Therapy  
EPSILON  
4, PAPANAMANTOPOULOU Str.  
Tel. 2107254360-2 fax. 210725436